Biodesix Test Identifies Patients with Likely Improved Survival on Afatinib Therapy
Clinical findings have shown that the VeriStrat test from Biodesix is prognostic for outcomes among patients with squamous cell carcinoma of the lung who are treated with afatinib.
Read More